Wednesday, November 19, 2014

EyewireTV —Actavis Buys Allergan, Valeant Buys Nicox, Vision for Mars Update

In this week's EyewireTV, in a blockbuster deal that will likely thwart a long and aggressive hostile takeover bid by Valeant, Actavis agrees to acquire Allergan for $66 billion in cash and stock; and Valeant acquires Nicox’s US diagnostics business, Nicox Inc., in a deal worth up to $20 million. Also, a team of researchers, NASA scientists, leading ophthalmologists, and business representatives, collectively known as the Vision for Mars team, makes several recommendations regarding various eye conditions in astronauts. (1282 Views)

Watch Video

Wednesday, November 12, 2014

EyewireTV — Allergan-Actavis Discussions, Phase 3 Dry Eye Study

In this week's EyewireTV, new reports emerge that Allergan is in talks with generic and specialty drugmaker Actavis about a possible takeover deal; and Eleven Biotherapeutics completes patient enrollment in its first phase 3 clinical study of EBI-005, its lead product candidate for dry eye disease. In the feature, three leading ophthalmologists discuss the advantages of having an integrated care model in their practice. (1763 Views)

Watch Video

Wednesday, November 05, 2014

EyewireTV — NASA Eye Health, Omidria CMS Pass-Through

In this week's EyewireTV, a new public-private partnership led by a NASA entity is formed with the task of safeguarding the eye during and after long-duration space travel; and Omeros receives transitional pass-through status from the Centers for Medicare & Medicaid Services for its lead product Omidria. Also, new research shows that the severity of AMD in one eye is associated with the incidence and progression of AMD in the other eye. (1765 Views)

Watch Video

Wednesday, October 29, 2014

EyewireTV — FDA LASIK Study, Allergan-Valeant Developments, Innovator Award

In this week’s EyewireTV, a large FDA-sponsored study evaluating the safety and effectiveness of LASIK shows high rates of patient satisfaction and a low prevalence of postoperative symptoms; Allergan reports strong third-quarter sales growth and raises its outlook, while Valeant hints that it may be raising its takeover bid. Also, Sue Washer, president and CEO of Applied Genetic Technologies, is named the recipient of the OIS@AAO Innovator Award. (1717 Views)

Watch Video

Tuesday, October 21, 2014

EyewireTV — Breaking Industry News From the AAO Meeting in Chicago

In this week's EyewireTV, releases preliminary data from its National Institutes of Health-sponsored Protocol T study, which examined the efficacy and safety of three anti-VEGF agents in patients with diabetic macular edema; and Abbott Medical Optics and Carl Zeiss Meditec enter a nonexclusive commercial collaboration in which AMO will sell and distribute Zeiss’ cataract surgery portfolio in the United States. Also, Carl Zeiss Meditec introduces its Cataract Suite Markerless range of products to the US market. (3494 Views)

Watch Video

Wednesday, October 15, 2014

EyewireTV — Lucentis Priority Review, Implantable Miniature Telescope, Eyewire Redesign

In this week's EyewireTV, the FDA grants priority review to Genentech’s biologics license application for Lucentis (ranibizumab) the treatment of diabetic retinopathy; and the FDA approves VisionCare Ophthalmic Technologies' Implantable Miniature Telescope for use in patients with bilateral end-stage AMD who are 65 or older. Also, EyewireTV News Director Stephen Daily provides details of the redesign of (1888 Views)

Watch Video

Wednesday, October 08, 2014

EyewireTV — New Eylea Indication, Second Sight AMD Study, Loteprednol Etabonate Study

In this week's EyewireTV, the FDA approves Regeneron’s Eylea (aflibercept) for the treatment of macular edema following retinal vein occlusion; and Second Sight Medical Products announces that its dry AMD feasibility study, the first study of retinal implants in patients with AMD, will begin in November. In the feature, we ask leading ophthalmologists and a practice administrator to share their thoughts on the potential to grow their practice through premium and elective services. (1488 Views)

Watch Video

Wednesday, October 01, 2014

EyewireTV — Ozurdex Expanded Indication, Iluvien FDA Approval, Avedro CXL Resubmission

In this week’s EyewireTV, the FDA approves an expanded indication for Allergan’s Ozurdex (dexamethasone intravitreal implant 0.7 mg) for the treatment of diabetic macular edema; and Alimera Sciences’ Iluvien (fluocinolone acetonide intravitreal implant 0.19 mg) receives FDA approval for the treatment of DME in patients who were previously treated with corticosteroids and did not have a clinically significant rise in IOP. Also, Avedro resubmits a new drug application to the FDA for its riboflavin ophthalmic solution and KXL System. (2031 Views)

Watch Video

Wednesday, September 24, 2014

EyewireTV — Allergan Considers Acquisition, Alcon Vitreoretinal Products, Vitra PDT CE Mark Approval

In this week's EyewireTV, Allergan is reportedly in advanced talks to buy Salix Pharmaceuticals. Such an acquisition, likely valued at more than $10 billion in cash, could derail Valeant’s attempt to buy Allergan; and Alcon introduces several new products in its surgical vitreoretinal portfolio, including the FINESSE Flex Loop, ULTRAVIT High Speed Vitrectomy Probes, and 27+ portfolio of gauge instruments. (1805 Views)

Watch Video

Tuesday, September 16, 2014

EyewireTV — Live Coverage of the ESCRS Meeting in London

In this week's EyewireTV, preliminary results of the Femtosecond Laser-Assisted Cataract Surgery (FLACS) study show that laser-assisted cataract surgery is as good as routine phacoemulsification but does not currently outperform it; and Carl Zeiss Meditec releases the IOLMaster 700, the first device with swept-source biometry. Also, TearScience introduces the LipiView II Ocular Surface Interferometer to assist in the diagnosis of meibomian gland dysfunction. (2360 Views)

Watch Video

Wednesday, September 10, 2014

EyewireTV — Beaver-Visitec Buys Endo Optiks, Allergan Special Meeting, CMS Data Release

In this week's EyewireTV, Beaver-Visitec International purchases Endo Optiks, a provider of microendoscopy products for the treatment of glaucoma and retinal diseases; and Allergan says Pershing Square Capital Management’s requests from more than 25% of Allergan shareholders are valid and comply with its bylaws, setting the stage for a special meeting. In this week’s feature, ophthalmologists provide their thoughts on the Centers for Medicare & Medicaid Services publicizing physician Medicare reimbursement data for the first time. (1489 Views)

Watch Video

Wednesday, September 03, 2014

EyewireTV — Allergan Shareholder Meeting Request, Avedro Buys IROC Innocross, Ozurdex EU Approval

In this week's EyewireTV, a Delaware Chancery Court decision could expedite Valeant’s request for a special shareholder meeting to oust Allergan’s directors; and Avedro purchases the assets of IROC Innocross, of Zug, Switzerland, the first company to commercialize a cross-linking device for the treatment of keratoconus and other corneal pathologies. Also, Allergan announces that Ozurdex (dexamethasone) is now approved in the European Union to treat patients with diabetic macular edema who are pseudophakic or who are considered insufficiently responsive to non-corticosteroids. (1518 Views)

Watch Video
Load More